Haematological cancer: Nilotinib reduces emergence of BCR–ABL mutations in CML


Chronic myeloid leukaemia (CML) is characterized by the presence of the Philadelphia chromosome (Ph) and its oncogenic product, the constitutively activated tyrosine kinase BCR–ABL. Following development of the selective BCR–ABL tyrosine kinase inhibitor (TKI) imatinib, the inhibition of BCR–ABL has become the standard of care for patients with CML… (More)
DOI: 10.1038/nrclinonc.2013.51